ATE355079T1 - Behandlung von prostata-krebs mit anti-erbb2 antikörpern - Google Patents

Behandlung von prostata-krebs mit anti-erbb2 antikörpern

Info

Publication number
ATE355079T1
ATE355079T1 AT00939992T AT00939992T ATE355079T1 AT E355079 T1 ATE355079 T1 AT E355079T1 AT 00939992 T AT00939992 T AT 00939992T AT 00939992 T AT00939992 T AT 00939992T AT E355079 T1 ATE355079 T1 AT E355079T1
Authority
AT
Austria
Prior art keywords
prostate cancer
treatment
erbb2 antibodies
erbb2
antibodies
Prior art date
Application number
AT00939992T
Other languages
English (en)
Inventor
Mark X Sliwkowski
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE355079T1 publication Critical patent/ATE355079T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00939992T 1999-06-25 2000-06-23 Behandlung von prostata-krebs mit anti-erbb2 antikörpern ATE355079T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14131599P 1999-06-25 1999-06-25

Publications (1)

Publication Number Publication Date
ATE355079T1 true ATE355079T1 (de) 2006-03-15

Family

ID=22495163

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00939992T ATE355079T1 (de) 1999-06-25 2000-06-23 Behandlung von prostata-krebs mit anti-erbb2 antikörpern

Country Status (18)

Country Link
US (2) US20060083739A1 (de)
EP (1) EP1189634B1 (de)
JP (2) JP4579471B2 (de)
KR (1) KR100754049B1 (de)
CN (1) CN100381172C (de)
AT (1) ATE355079T1 (de)
AU (1) AU779209B2 (de)
BR (1) BR0012195A (de)
CA (1) CA2383493C (de)
CY (1) CY1107637T1 (de)
DE (1) DE60033658T2 (de)
DK (1) DK1189634T3 (de)
ES (1) ES2282120T3 (de)
IL (1) IL147017A0 (de)
MX (1) MXPA01013395A (de)
PT (1) PT1189634E (de)
WO (1) WO2001000238A1 (de)
ZA (1) ZA200110088B (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
AR024464A1 (es) * 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
EP2977063A1 (de) * 1999-06-25 2016-01-27 Genentech, Inc. Methoden zur Behandlung unter Verwendung von Anti-ErbB Antibody-Maytansinoid Konjugaten
US6825333B1 (en) 1999-08-20 2004-11-30 Chiron Corporation EGFH2 genes and gene products
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
WO2001089566A1 (en) 2000-05-19 2001-11-29 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
EP2270049A3 (de) * 2002-04-12 2011-03-09 Medimmune, Inc. Rekombinante Anti-Interleukin-9-Antikörper
AU2003237367A1 (en) 2002-06-03 2003-12-19 Chiron Corporation Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
SI1509230T1 (sl) * 2002-06-05 2007-06-30 Cedars Sinai Medical Center Gefitinib (iressa) za zdravljenje raka
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
CN100522998C (zh) 2003-10-01 2009-08-05 协和发酵麒麟株式会社 抗体的稳定化方法和被稳定的溶液状抗体制剂
AU2003280688A1 (en) * 2003-10-31 2005-05-19 Kurume University Combination therapy of peptide vaccination and estramustine treatment
JP4905624B2 (ja) * 2003-10-31 2012-03-28 学校法人 久留米大学 ペプチドワクチン投与およびエストラムスチン処置の併用療法
AU2005232657B2 (en) 2004-04-08 2010-12-16 David B. Agus ErbB antagonists for pain therapy
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
UA90480C2 (uk) 2004-07-22 2010-05-11 Джэнэнтэк, Инк. Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2587519A1 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
EP3698807A1 (de) 2005-01-21 2020-08-26 Genentech, Inc. Fixe dosierung von her-antikörpern
RS53128B (sr) * 2005-02-23 2014-06-30 Genentech Inc. Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
EP1913958B1 (de) * 2006-08-03 2009-12-23 Sanofi-Aventis Antitumorale Zusammensetzungen enthaltend Acetylcyclopropyl Docetaxel und Trastuzumab
AU2007287794B2 (en) 2006-08-21 2013-03-28 F. Hoffmann-La Roche Ag Tumor therapy with an anti-VEGF antibody
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
CN101918844A (zh) * 2007-06-18 2010-12-15 米迪缪尼有限公司 表达epha2和erbb2的细胞的协同治疗
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
EA021967B1 (ru) 2008-01-03 2015-10-30 Дзе Скриппс Рисерч Инститьют Доставка антител посредством модульного домена распознавания
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
NZ587706A (en) 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
JP2012507299A (ja) 2008-10-31 2012-03-29 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｇｈｔ標的分子およびその使用
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
ES2519348T3 (es) 2010-02-18 2014-11-06 Genentech, Inc. Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
NZ604007A (en) 2010-05-27 2015-03-27 Genmab As Monoclonal antibodies against her2 epitope
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
EP2655413B1 (de) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
BR112014003431A2 (pt) 2011-08-17 2017-06-13 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013096812A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
RU2692773C2 (ru) 2012-11-30 2019-06-27 Ф.Хоффманн-Ля Рош Аг Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1
KR20140103554A (ko) * 2013-02-18 2014-08-27 고려대학교 산학협력단 sLZIP 단백질을 포함하는 안드로겐 의존성 전립선암 치료용 의약 조성물
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
MY173295A (en) 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
BR112016024789A2 (pt) 2014-04-25 2017-10-24 Genentech Inc métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe
JP6822980B2 (ja) 2015-05-30 2021-01-27 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性転移性乳癌の治療方法
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
EP3534948A1 (de) 2016-11-04 2019-09-11 Genentech, Inc. Behandlung von her2-positivem brustkrebs
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
DK3570884T3 (da) 2017-01-17 2020-11-30 Genentech Inc Subkutane HER2-antistofformuleringer
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935341A (en) * 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5169774A (en) * 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5824311A (en) * 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
EP0474727B1 (de) * 1989-05-19 1997-07-23 Genentech, Inc. Her2 extrazellulare domäne
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US6884418B1 (en) * 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
DE69033842T2 (de) * 1989-08-04 2002-06-20 Schering Ag Äusserliche domäne von c-erbb-2:gp75
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
ATE153858T1 (de) * 1990-04-06 1997-06-15 Univ Pennsylvania Ligand für das neu-gen-produkt
US5578482A (en) * 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
ATE145428T1 (de) * 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5834229A (en) * 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
EP0590058B1 (de) * 1991-06-14 2003-11-26 Genentech, Inc. Humanisierter Heregulin Antikörper
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1993003741A1 (en) * 1991-08-22 1993-03-04 Becton, Dickinson & Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
US5288477A (en) * 1991-09-27 1994-02-22 Becton, Dickinson And Company Method for prognosticating response to cancer therapy
FI941572L (fi) * 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
CA2372813A1 (en) * 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO1994009022A1 (en) * 1992-10-09 1994-04-28 Oncor, Inc. Methods for the detection of chromosome structural abnormalities by in situ hybridization to fixed tissue
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
WO1995030331A1 (en) * 1994-05-05 1995-11-16 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US5910486A (en) * 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5480698A (en) * 1994-09-13 1996-01-02 Hayman-Chaffey; Charles Acrylic or polycarbonate sheet-lacquer laminates and articles of furniture made therefrom
US5846749A (en) * 1994-10-12 1998-12-08 The Regents Of The University Of California Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
US5804396A (en) * 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5783404A (en) * 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
US5663144A (en) * 1995-05-03 1997-09-02 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
US6410690B1 (en) * 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
WO1997000271A1 (en) * 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
ATE290595T1 (de) * 1996-07-12 2005-03-15 Genentech Inc Gamma-heregulin
CA2744096C (en) * 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US5789522A (en) * 1996-09-06 1998-08-04 Shipley Company, L.L.C. Resin purification process
CN101412758A (zh) * 1996-10-18 2009-04-22 基因技术股份有限公司 抗ErbB2抗体
US5885864A (en) * 1996-10-24 1999-03-23 Micron Technology, Inc. Method for forming compact memory cell using vertical devices
US5994071A (en) * 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6358682B1 (en) * 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
CA2357525A1 (en) * 1999-01-27 2000-08-03 Cornell Research Foundation, Inc. Treating cancers associated with overexpression of her-2/neu
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
NZ546251A (en) * 2000-12-01 2008-01-31 Response Genetics Inc Method of determining epidermal growth factor receptor gene expression in a parafin embedded tiasue sample and correlation of levels thereof with survival rates
US6582919B2 (en) * 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates

Also Published As

Publication number Publication date
ES2282120T3 (es) 2007-10-16
KR100754049B1 (ko) 2007-08-31
CA2383493A1 (en) 2001-01-04
DK1189634T3 (da) 2007-06-25
EP1189634B1 (de) 2007-02-28
JP4579471B2 (ja) 2010-11-10
JP2009269928A (ja) 2009-11-19
PT1189634E (pt) 2007-06-06
JP2003503361A (ja) 2003-01-28
CY1107637T1 (el) 2013-04-18
WO2001000238A1 (en) 2001-01-04
DE60033658D1 (de) 2007-04-12
BR0012195A (pt) 2002-07-23
US20090087432A1 (en) 2009-04-02
AU779209B2 (en) 2005-01-13
CN1379684A (zh) 2002-11-13
IL147017A0 (en) 2002-08-14
DE60033658T2 (de) 2007-11-22
US20060083739A1 (en) 2006-04-20
CN100381172C (zh) 2008-04-16
MXPA01013395A (es) 2003-09-04
AU5499200A (en) 2001-01-31
EP1189634A1 (de) 2002-03-27
CA2383493C (en) 2010-08-10
ZA200110088B (en) 2002-08-26
KR20020069104A (ko) 2002-08-29

Similar Documents

Publication Publication Date Title
DE60033658D1 (de) Behandlung von prostata-krebs mit anti-erbb2 antikörpern
ATE415979T1 (de) Behandlung mit anti-erbb2 antikörpern
TR200103756T2 (tr) Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi.
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
DE69942827D1 (de) Verwendung der epothilons zur behandlung der krebs
DE59709437D1 (de) Neue phenanthridine
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
EA199800391A1 (ru) Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору
DE69633679D1 (de) Substituierte aryl-oder heteroarylamide mit retinoid-ähnlicher biologischer aktivität
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
DE3888378D1 (de) Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE224386T1 (de) Neue in 6-position substituierte phenanthridine
DE60023982D1 (de) System zur Behandlung von benigner Prostatahyperplasie
EP1320376A4 (de) Behandlung von prostatakrebs
DK1083903T3 (da) Brobundne indenopyrrolocarbazoler
DE60030554D1 (de) Verwendungen von et743 zur behandlung von krebs
DZ2665A1 (fr) Conjugués utiles pour le traitement du cancer de la prostate.
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
ATE250580T1 (de) Substituierte pyridino-arylpiperazine zur behandlung benigner prostatahyperplasie
DE69601154D1 (de) Zubereitungen für die Behandlung von Hepatitis C
TR200003084T2 (tr) Paroxetine askorbat
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial
ECSP982362A (es) Compuestos de quinolina y quinazolina utiles en terapia

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1189634

Country of ref document: EP